ArticleInternational journal of hematology2020
Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan.
Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome.Frontiers in medicine · 2026Article
- Incidental Cold Agglutinins in Lung Transplant Recipients.Transplantation direct · 2025Article
- The Role of Cold Agglutinins Screening in Cardiac Surgery: Necessity or Redundancy?Sisli Etfal Hastanesi tip bulteni · 2025Article
- Autoimmune haemolytic anaemias.Nature reviews. Disease primers · 2024Review
- Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.Current oncology reports · 2024Review
- Organizing Pneumonia in a Case of Cold Agglutinin Disease with Pulmonary Thrombosis.Internal medicine (Tokyo, Japan) · 2024Article
- Infrequent Thrombotic Complications in Japanese Patients with Warm Autoimmune Hemolytic Anemia.Internal medicine (Tokyo, Japan) · 2023Article
- Sutimlimab for the Treatment of Cold Agglutinin Disease.HemaSphere · 2023Review
- Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?Frontiers in immunology · 2023Review
- Clinical and laboratory characteristics of patients with cold agglutinin disease: A retrospective analysis at a tertiary medical center.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease (CAD) is a rare, complement-mediated autoimmune hemolytic anemia. Patients with CAD in the United States and Europe have an increased incidence of thromboembolism (TE), but comparable information for patients in other regions is lacking. Thus, we examined TE risk for patients with CAD in Japan. Patients with CAD (at least three claims with a CAD diagnosis; Japanese Disease Code 2830009) and non-CAD controls were retrospectively identified (2008-2017) from a large hospital-based administrative claims dataset in Japan. Cohorts were compared using conditional logistic regression. We identified 344 patients with CAD (53.2% female; mean age: 66.8 years) and 3440 matched controls. Patients with CAD had higher TE rates than controls (34.9% vs. 17.9%; P < 0.0001). Both arterial and venous TEs were increased in the CAD group when compared with the control group (25.0% vs. 4.6% and 8.4% vs. 4.0%, respectively; both P < 0.0001). Most arterial TEs in the CAD cohort (87.2%) were myocardial infarctions. The overall odds ratio for TE development in CAD was 2.81 (95% confidence interval 2.18-3.61). CAD in Japan is characterized by an increased risk of TE. The rate of arterial TEs was particularly high in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.